Giannis Mountzios: Are we treating our NSCLC patients with the optimal dose and duration of immunotherapy?
Giannis Mountzios, Director of the 4th Oncology Department and Clinical Trials Unit at Henry Dunant Hospital Center, shared a post on X about a recent paper by him and colleagues published in Journal of Clinical Oncology:
“Are we treating our NSCLC patients with the optimal dose and duration of immunotherapy?
Academia has the ethical duty to explore de-escalation strategies to maintain efficacy and reduce toxicity and cost.
In the Journal of Clinical Oncology, a fascinating review led by Jordi Remon, Benjamin Besse, Lizza Hendriks, Martina Bortolot and coauthors.
Happy to contribute to this global call for action.”
Authors: Jordi Remon, Benjamin Besse, Giannis Mountzios, Lizza Hendriks, Martina Bortolot et al.
More posts featuring Giannis Mountzios.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023